Merck & Co News

Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy

ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrangement with the Serum Institute of India, the world's l

Benzinga12:19 ET

Janux Therapeutics Gains Amid Renewed Takeover Speculation

Seeking AlphaMay 2 16:09 ET

Express News | NYSE Order Imbalance 431988.0 Shares on Sell Side

ReutersMay 2 15:50 ET

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

BenzingaMay 2 13:35 ET

Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration

After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE:MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after

BenzingaMay 2 12:53 ET

Cerevance Receives Milestone Payment Under Alzheimer's Collaboration With Merck

Seeking AlphaMay 2 12:40 ET

Express News | Merck & Co Inc : Jefferies Raises Target Price to $150 From $145

ReutersMay 2 02:08 ET

15 Best Places to Retire in Florida That You've Never Heard Of

Yahoo FinanceMay 1 18:52 ET

Express News | NYSE Order Imbalance 85022.0 Shares on Buy Side

ReutersMay 1 15:50 ET

Redburn Atlantic Adjusts Price Target on Merck to $148 From $142

Merck & Company (MRK) has an average outperform rating and a price target range of $118 to $155, according to analysts polled by Capital IQ. Price: 130.91, Change: +1.69, Percent Change: +1.31

MT NewswiresMay 1 08:21 ET

Express News | Merck's Phase 3 KEYNOTE-811 Trial Of Keytruda Met Dual Primary Endpoint of Overall Survival as First-Line Treatment Of HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

BenzingaMay 1 07:17 ET

Express News | Merck & Co Inc - Safety Profile of Keytruda in Trial Consistent With That Observed in Previously Reported Studies, No New Safety Signals Identified

ReutersMay 1 07:16 ET

Express News | Merck Announces Phase 3 Keynote-811 Trial Met Dual Primary Endpoint of Overall Survival (Os) as First-Line Treatment in Patients With Her2-Positive Advanced Gastric or Gastroesophageal Junction (Gej) Adenocarcinoma

ReutersMay 1 07:15 ET

Is Merck (NYSE:MRK) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe

Simply Wall StApr 30 07:02 ET

Express News | NYSE Order Imbalance 151490.0 Shares on Sell Side

ReutersApr 29 15:50 ET

Merck Late-stage Data Strengthens Profile of Pneumonia Vaccine Candidate

Seeking AlphaApr 29 10:20 ET

Jumo Health to Lead a Roundtable Discussion on Authenticity and the Patient Voice at the Annual Health Equity in Clinical Trials Congress

NEW HAVEN, Conn., April 29, 2024 /PRNewswire/ -- Jumo Health—a global provider of age-appropriate, culturally relevant medical education—today announced that Kevin Aniskovich, the Company's President

PR NewswireApr 29 09:52 ET

Express News | Merck: Immune Responses Elicited by V116 Were Superior for Nine Serotypes Included in V116 but Not Ppsv23, as Measured by Opa Gmt Ratios at Day 30

ReutersApr 29 09:00 ET

Express News | Merck & Co Inc: V116 Elicited Immune Responses That Were Noninferior Compared to Ppsv23 for 12 Serotypes (or Strains) Common to Both Vaccines

ReutersApr 29 09:00 ET

Express News | Merck & Co Inc: V116 Had a Safety Profile Comparable to Ppsv23

ReutersApr 29 09:00 ET